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Objectives: To compare the donor outcomes of living donor kidney trans-
plantation between standard donors (SDs) and marginal donors (MDs) in-
cluding diabetic patients (MD+DM).
Methods: MDs were defined according to Japanese guideline criteria: (a) age
>70‐years, (b) blood pressure ≤130/80mmHg on hypertension medicine, (c)
body mass index >25 to ≤32 kg/m2, (d) 24‐h creatinine clearance ≥70 to
<80ml/min/1.73 m2, and (e) hemoglobin A1c > 6.2 or ≤6.5 with oral diabetic
medicine. Fifty‐three of 114 donors were MDs. We compared donor kidney
functions until 60 months postoperatively.
Results: No kidney function parameters were different between SDs and
MDs. When comparing SD and MD+DM, MD+DM had a lower post-
operative eGFR (48 vs. 41 (1 (month), p= .02), 49 vs. 40 (12, p< .01), 48 vs. 42
(24, p= .04), 47 vs. 38 (36, p= .01)) and the percentage of residual eGFR (SD
vs. MD+DM: 63 vs. 57 (1 (month), p< .01), 63 vs. 57 (2, p< .01), 64 vs. 56 (12,
p< .01), 63 vs. 57 (24, p< .01), 63 vs. 52 (36, p= .02)). However, when MD
with a single risk factor of DM was compared to SD, the difference dis-
appeared. Nine out of 12 (75%) MD+DM had ≥2 risk factors.
Conclusions: Although long‐term observation of donor kidney function is ne-
cessary, careful MD+DM selection had the potential to expand the donor pool.
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standard donor; Tac‐ER, extended release tacrolimus.
1 | INTRODUCTION
Kidney transplantation is the most useful treatment for
patients with end‐stage renal disease (ESRD). The pre-
valence of ESRD in Japan was the second highest in the
world in 2016, with 2599 cases per million of the general
population.1 Despite the increasing number of ESRD
patients, the donor shortage has been a serious problem
worldwide, particularly in Japan, with only 1865 (0.5%)
kidney transplantations compared with approximately
340,000 dialysis patients in 2018.2,3 Furthermore, most
transplants were from living‐donors (1683 cases), with
only 55 coming from non‐heart‐beating donors and 127
coming from heart‐beating donors.3
In 2014, the original marginal donor (MD) criteria
were established in Japan with reference to the standards
for live‐donor kidney transplants put forth by the Am-
sterdam Forum.4,5 To address the gap between the
number of patients awaiting kidney transplants and the
number of kidney donors, the number of MD with bor-
derline kidney conditions and potential to be kidney
donors is increasing following detailed preoperative
testing. MDs may now include people of older age, peo-
ple with hypertension (HTN), and those who are obese,
have mild kidney dysfunction, or diabetes mellitus (DM).
Other factors also playing a role in the increase in MDs
are an aging population, an increase in the number of
people with lifestyle‐related diseases, and an increase in
the number of living‐donor kidney transplantations
among couples or parents and children. One of the most
notable Japanese criteria for kidney transplants is that
donors with DM are approved if their blood glucose is
well‐controlled without the need for insulin. This ex-
ception is not currently permitted in most other countries
because the presence of DM in donor is not allowed in
the Amsterdam Forum.4,5 However, the adequacy of MD
with DM (MD+DM) is currently unknown, since the
treatment for DM continues to evolve.
A total of 19.6% of kidney donors in Japan had a
history of HTN and 4.1% of kidney donors had a history
of diabetes in 2018 and those rates are incrising.3,6 In the
same year, 45.2% of living donors with HTN were over
60 years old and 15.4% with diabetes were over 70 years
old.3 In the United States, 5.2% of kidney donors were
older than 65 years, indicating that living kidney donors
were generally older in Japan.7
It is essential that a donated kidney is functionally
adequate, and also that the selected MD's kidney func-
tion and health condition is not affected after the dona-
tion in the long‐term. The definition of marginal criteria
differs by reports; however, several reports have in-
dicated the usefulness and safety of kidney donation
from MDs.8,9 In contrast, there are reports that kidney
donations from MD may result in worse long‐term out-
comes than from standard donor (SD) for both the re-
cipients and donors, underscoring the need for careful
selection.10–12
This study investigated the adequacy of the current
selection criteria for MDs based on the Japanese guide-
lines, including those with DM, and assessed the changes
in renal function of donors after donation.
2 | MATERIALS AND METHODS
2.1 | Patients
In this study, we retrospectively evaluated 114 patients
who underwent donor nephrectomy at our institution
between May 2009 and April 2020. One hundred ten
cases (96%) of donor nephrectomies were performed la-
paroscopically. We compared the backgrounds of donors
at the time of transplantations including age, gender,
marital status and each marginal factor. Based on the
guidelines for living‐donor renal transplantations in Ja-
pan, we defined donors as marginal when at least one of
the following conditions was met: (a) age >70 years, (b)
blood pressure (BP)≤ 130/80mmHg with taking anti-
hypertensive drugs, (c) 25 < body mass index (BMI)
≤ 32 kg/m2, (d) 70≤ creatinine clearance <80ml/min/
1.73m2 per 24‐h urine collection, (e) 6.2 < hemoglobin
A1c (HbA1c)≤ 6.5 without oral medication for diabetes
or ≤6.5 with oral medication for diabetes.4 All cases met
the donor criteria with a urine albumin‐creatinine ratio
(ACR) of <30mg/g.
Our retrospective study complied with the standards
of the Declaration of Helsinki and current ethical
guidelines, and was approved by the Okayama University
Institutional Review Board (Registration No.: 1908‐026).
We obtained written informed consent from all patients
for the use of their clinical records.
2.2 | Induction protocol
Triple therapy, including extended‐release tacrolimus
(Tac‐ER), mycophenolate mofetil (MMF), and pre-
dnisolone plus basiliximab, was the induction therapy.
Basiliximab was administered on the day of the trans-
plantation and 4 days later. ABO major mismatch, ABO
minor mismatch, preformed DSA, and focal segmental
glomerulosclerosis cases received a 200mg/body dose of
rituximab 1–2 weeks before the date of renal transplan-
tation in addition to induction therapy. Tac‐ER, MMF,
and prednisolone were also used as maintenance
therapy.
2 | YOSHINAGA ET AL.
2.3 | Renal function
Donors kidney function transitions were compared. To
evaluate kidney function, serum creatinine (sCr), esti-
mated glomerular filtration rate (eGFR), and urine
protein‐creatinine ratio (PCR) were measured pre-
operatively and postoperatively at 1, 12, 24, 36, 48, and
60 months. The percentage of residual eGFR from
baseline was also calculated. The baseline eGFR was
defined as preoperative one. ACR was also assessed
preoperatively and at discharge. MD+DM were subse-
quently compared with SDs in the same way.
2.4 | Statistical analysis
All statistical analyses were performed using EZR version
1.41 (Saitama Medical Center, Jichi Medical University,
Saitama, Japan), a graphical user interface for R.13 Donor's
characteristics and kidney function data were compared
between patients with SD and MD using Fisher's exact test
for categorical variables, and Mann–Whitney U test was
used for continuous variables. p< .05 were considered sig-
nificantly different.
3 | RESULTS
There were 61 SDs and 53 MDs. As shown in Figure 1,
20 donors met the MD criteria despite having multiple risk
factors. Table 1 shows the characteristics of donors and
Table 2 lists the risk breakdown for MDs. Only median age
was significantly different between SD and MD (57 vs.
64 years, respectively; p< .01), but gender and marital status
were similar between groups. Median age of MD+DM was
71 (interquartile range [IQR]: 68–74) and that of MDwithout
DM was 62 (IQR: 56–66). HTN and high BMI were the most
common risk factor among MD (n=25) and suboptimal
kidney function was the least common risk factor (n=5).
Preoperatively, and up to 60 months postoperatively,
donor kidney function did not differ significantly between
the SD and MD groups (Figure 2). In that order, ACR
preoperatively and at discharge, respectively, in donors
was 6 versus 7 (p= .16) and 8 versus 9 (p= .55). All donors
had a good postoperative course, with no cases of dialysis
induction or death.
The comparison between SD and MD+DM in donors
could be analyzed for 48 months. Postoperative eGFR was
lower in MD+DM, and residual rate of eGFR from baseline
in MD+DMwas significantly higher at any point compared
with those in SDs. No significant differences between SDs
and MD+DM were found in sCr, PCR (Figure 3) and ACR
(preoperatively: 6 vs. 8, p= .04; at discharge: 8 vs. 9, p= .99).
However, when compared to MD+DM without multiple
risk factors for 36 months, the difference disappeared. Nine
out of 12 (75%) MD+DM had ≥2 risk factors per the MD
criteria (Figure 4).
4 | DISCUSSION
The data from our study suggested that donor kidney func-
tion did not differ significantly between the SD and MD
groups. However, we should carefully followMD+DMwith
multiple risk factors since they had a lower kidney function
compared with SD.
Previous reports comparing eGFR between SD and MD
groups showed that MDs had a lower eGFR preoperatively
and postoperatively; however, no significant differences in
the rate of residual of eGFR were reported.14–16 Dols et al.15
showed no postoperative differences in the decline of eGFR
and in proteinuria defined as ≥3.0 g/L between donors aged
<60 and ≥60 years. The Kidney Disease: Improving Global
Outcomes guidelines revised the classification system for
chronic kidney disease to include albuminuria.17 The earliest
clinical course of diabetic nephropathy is recognized by
measuring microalbuminuria. Of note, ACR is not an ac-
ceptable measurement in Japan national health insurance
except when diabetes is diagnosed. PCR is measured instead
because proteinuria is also reported to predict the risk of
ESRD.18 We were able to measure ACR preoperatively, at
discharge and at 12 months postoperatively and found no
significant differences between groups. Despite the limitation
of a short observation period of 5 years, none of the donors
in this study experienced ESRD or died after donating a
kidney. In summary, our selection of MDs was exceedingly
FIGURE 1 Study flow chart. The flow chart shows the
derivation of the two groups. BMI, body mass index; BP, blood
pressure; CCr, creatinine clearance; DM‐MD, marginal donor with
diabetes mellitus; HbA1c, hemoglobin A1c; MD, marginal donor;
SD, standard donor
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careful and is reflected in the results as no significant dif-
ference in the preoperative eGFR of MDs when compared
with SDs.
We also compared the changes in renal function be-
tween SD and MD+DM. Our results showed that the
postoperative eGFR was significantly lower in MD+DM.
However, the differences disappeared comparing with the
MD+DM without multiple risk factors. Our results in-
dicated that a kidney transplantation from MD+DM was
possible. It will help expand the donor pool. However, one
should be careful to use MD+DM with multiple risk
factors especially when they were young. The average age
of MD+DM was 71 years in our study.
Systolic BP>140/90mmHg is important cardiovascular
risk for both the recipient and donors during and after kid-
ney transplantation.11,19 Kidney donation is permitted in the
event of mild‐to‐moderate HTN that is controlled with one
or a combination of two antihypertensive drugs providing
significant end‐organ damage has been excluded.10 Bozkurt
et al.11 reported that there is no definitive evidence to suggest
a direct effect of high BP on graft rejection after renal
transplantation. At our institution, 20.2% of donors had
controlled HTN preoperatively. Of the SDs, 12 had systolic
BP>140 postoperatively, and 5 of them started receiving one
or more antihypertensive medications. The time to medica-
tion ranged from 1 to 62 months postoperatively. The other 7
have been treated with lifestyle changes including salt re-
duction or weight reduction.
Obesity is one of the significant risks affecting long‐term
outcomes after kidney donation. BMI> 32 kg/m2 is a
TABLE 1 Donor's characteristics
Total cases, n (%)
Total SD MD
p value114 (100) 61 (54) 53 (46)
Donor's background
Age, median (IQR) 60 (53–66) 57 (51–62) 64 (57–71) <.001
Sex (male), n (%) 49 (43) 30 (49) 19 (36) .186
marital, n (%) 45 (39) 21 (34) 24 (45) .255
Marginal factor
Age >70‐year‐old, n (%) 15 (13) 0 (0) 15 (28) <.001
BP ≤130/80mmHg with taking
antihypertensive drugs, n (%)
25 (22) 0 (0) 25 (47) <.001
25 < BMI≤ 32, n (%) 25 (22) 0 (0) 25 (47) <.001
70≤CCr < 80ml/min/1.73m2 in 24‐h
urine collection test, n (%)
5 (4) 0 (0) 5 (9) .020
6.2 <HbA1c≤ 6.5 without any
medication or HbA1c≤ 6.5 with oral
medication for diabetes, n (%)
12 (11) 0 (0) 12 (23) <.001
Abbreviations: BP, blood pressure; BMI, body mass index; CCr, creatinine clearance; HbA1c, hemoglobin
A1c; IQR, interquartile range; MD, marginal donor; SD, standard donor.
TABLE 2 The risk breakdown for marginal donors
Marginal factors
Number Risk Number of MDs (%)





2 Age +HT 2 (4) 17 (32)
Age + BMI 1 (2)
Age +DM 4 (8)
HT+ BMI 7 (13)
HT+ CCr 2 (4)
BMI +DM 1 (2)
3 Age +HT+BMI 1 (2) 3 (6)
Age +HT+DM 1 (2)
HT+ CCr +DM 1 (2)
4 Age +HT+BMI +DM 2 (4) 2 (4)
Abbreviations: BMI, body mass index; CCr, creatinine clearance; DM,
diabetes mellitus; HTN, hypertension.
aAge > 70‐year‐old.
bBlood pressure ≤130/80mmHg with taking antihypertensive drugs.
c25 < BMI≤ 32.
d70≤CCr < 80ml/min/1.73m2 in 24‐h urine collection test.
e6.2 < hemoglobin A1c≤ 6.5 without any medication or hemoglobin
A1c≤ 6.5 with oral medication for diabetes.
Percentages does not add up to 100% due to rounding.
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contraindication for kidney donation according to the Japa-
nese criteria.4 Two obesity‐related disorders can cause kid-
ney disease: (1) glucose intolerance and HTN associated with
obesity, and (2) obesity‐related glomerulopathy, caused by
obesity itself.20 No consensus has been reached as to whether
obesity is a risk for the decline of kidney function in do-
nors.21,22 There is a report indicating that the incidence of
HTN and other cardiovascular diseases in obese donors was
higher than in nonobese donors.23 A donor nephrectomy is a
more difficult procedure to perform in a living donor who is
obese. At our institution, we have never performed donor
nephrectomy until a donor's BMI is <28.3 kg/m2 after
dieting.
All donors have visited the hospital at 1 month,
2 months, and then every year after kidney transplanta-
tion to check their health status, including HTN, obesity,
decreased kidney function and DM. When the results of
blood and urine examination and vital checks indicate
the need for intervention, we have actively referred them
to medical specialists and provided nutritional counsel-
ing. Our strict MD selection and careful postoperative
follow‐up has contributed to no donor on dialysis after
kidney transplantation.
All donors have visited the hospital at 1 month,
2 months, and then every year after kidney transplantation
to check their health status, including HTN, obesity, de-
creased kidney function and DM. When the results of blood
sampling and vital checks indicate the need for intervention,
we have actively referred them to medical specialists and
provided nutritional counseling. These severe MD selections
and careful postoperative follow‐up have resulted in no do-
nor being placed on dialysis intervention after kidney
transplantation.
Comparing with the fact that MDs were 23%–29% in
previous Japanese reports,14,16 our MD rate is as high as
46%. MD's postoperative kidney function was not differ-
ent from those of SD during the first 5 years. Our data
suggested that MD including MD+DM is acceptable in
carefully selected population. Especially, we selected
MD+DM very carefully. We avoided young donor if a
donor has DM. Median age of MD+DM was 71 (IQR:
68–74) and that of MD without DM was 62 (IQR: 56–66).
We think that MD+DM is acceptable if donor is rela-
tively aged. We live in an aging society and lifestyle‐
related diseases increase. Our strategy will help expand
the donor pool.
FIGURE 2 Kidney function transition of donors over 60 months in SD and MD groups. All kidney functions were similar between
groups, except for the residual rate of eGFR at 60 months postoperatively (SD vs. DM; 61 vs. 73%, p< .01). eGFR, estimated glomerular
filtration rate, MD, marginal donor; PCR, urine protein‐creatinine ratio; sCr, serum creatinine; SD, standard donor
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This study has some limitations. First, this was a
small, retrospective study performed at a single center
and thus has the potential for selection bias. Second, our
observation period is only 5 years. Third, Japan has as
high as 90% of living‐donor kidney transplantations,
whereas in most countries kidneys are acquired from
deceased donors.3 The recipient's primary disease and
the marginal risk factors are disproportionate among
FIGURE 3 Kidney function transition of donors over 48 months in SD and DM‐MD. A significant difference in median parameter
values was observed at 1 month (48 vs. 41 ml/min/1.73m2, p= .02), 12 months (49 vs. 40 ml/min/1.73m2, p= .01), 24 months (48 vs.
42 ml/min/1.73m2, p= .04), and 36 months (47 vs. 38 ml/min/1.73m2, p= .01) during the transition of eGFR. The residual rate of eGFR was
lower in the DM‐MD versus the SD group. Other kidney functions were similar between groups. eGFR, estimated glomerular filtration rate;
DM‐MD, marginal donor with diabetes mellitus; PCR, urine protein‐creatinine ratio; sCr, serum creatinine; SD, standard donor
FIGURE 4 eGFR transition and the residual rate between the SD group and the MD group with the single risk factor of DM. DM,
diabetes mellitus; eGFR, estimated glomerular filtration rate; SD, standard donor
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countries. Although it is necessary to further verify the
validity of our results, this study is significant in terms of
expanding the donor pool. Third, we used sCr and eGFR
as biomarkers of kidney function. Other data, such as
serum cystatin C, should be examined in the future for
the accurate evaluation of kidney function.24 Fourth,
there is the lack of the information about the graft
function outcomes in the recipients. Finally, we also
think it is meaningful to compare the pathological
changes in 0‐time biopsy between the SD and MD group,
such as arteriosclerosis, arteriolosclerosis, interstitial fi-
brosis and tubular atrophy, glomerulosclerosis rate and
glomerular abnormality. We are currently writing dif-
ferent papers on this topic.
Despite these limitations, this study demonstrates
the safety and potential of kidney donations for MDs.
The kidney function of MDs was not different when
compared with SD during the first 5 years. Long‐term
observation is needed in the future. Greater attention
needs to be taken in the selection of MD + DM in
terms of postoperative kidney function, particularly
when MD candidates present with multiple risk
factors.
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